摘要
在世界范围内的药物投递系统都进行着深入地研究,特别是在肿瘤研究。事实上,在某些情况下,如骨转移,纳米药物可能是在治疗和早期癌灶成像最后和最好的选择。核医学已使用标记的99mTc MDP放射性药物许多年了;然而,其使用的纳米放射性药物非常新颖的并且创造一个新方案以提供一种新的方式建立放射技术。在这项研究中,我们开发并测试了纳米MDP标记在骨肿瘤转移和结果表明,它可以在患者中起效。然而,进一步的实验是必需的,以便在开始应用于人类。
关键词: 骨,纳米技术,肿瘤,放射性药物。
图形摘要
Current Cancer Drug Targets
Title:Nanoradiopharmaceuticals for Bone Cancer Metastasis Imaging
Volume: 15 Issue: 5
Author(s): Bianca Feliciano Coelho, Marta de Souza Albernaz, Alexandre Iscaife, Katia Ramos Moreira Leite and Mara de Souza Junqueira, Emerson Soares Bernardes, Emerson Oliveira da Silva and Ralph Santos-Oliveira
Affiliation:
关键词: 骨,纳米技术,肿瘤,放射性药物。
摘要: Drug delivery systems are under intense investigation all around the world, especially in oncology research. Indeed, in some cases, like bone metastasis, nanodrugs may represent the last and best choice for both treatment and imaging of early cancer foci. Nuclear medicine has been using MDP labelled with 99mTc as radiopharmaceuticals for many years; however, their use as nanoradiopharmaceuticals is very innovative and creates a new way to establish radiopharmacy in this new scenario offered by nanotechnology. In this study we developed and tested nano-MDP-labelled with 99mTc in rats induced with bone cancer metastasis and the results showed that it may work in patients. However, some further experiments are required in order to initiate protocols in humans.
Export Options
About this article
Cite this article as:
Bianca Feliciano Coelho, Marta de Souza Albernaz, Alexandre Iscaife, Katia Ramos Moreira Leite and Mara de Souza Junqueira, Emerson Soares Bernardes, Emerson Oliveira da Silva and Ralph Santos-Oliveira , Nanoradiopharmaceuticals for Bone Cancer Metastasis Imaging, Current Cancer Drug Targets 2015; 15 (5) . https://dx.doi.org/10.2174/1568009615666150407125020
DOI https://dx.doi.org/10.2174/1568009615666150407125020 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Considerations of Focal Drug Delivery in Cancer Treatment
Current Drug Delivery Characterization of Molecular and Functional Alterations of Tumor Endothelial Cells to Design Anti-Angiogenic Strategies
Current Vascular Pharmacology Cancer-related Fatigue, Inflammation and Thyrotropin-releasing Hormone
Current Aging Science Senescence and Cell Death Pathways and Their Role in Cancer Therapeutic Outcome
Current Medicinal Chemistry PET Radiopharmaceuticals for Personalized Medicine
Current Drug Targets Current Status and Perspectives in Peptide Receptor Radiation Therapy
Current Pharmaceutical Design Regulation of p53 Activity
Current Chemical Biology Doxorubicin Sensitizes the Non-Small Cell Lung Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated (TRAIL) Apoptosis In Vitro but not In Vivo
Letters in Drug Design & Discovery Editorial (Thematic Issue: Nucleoside/tide Analogues in Modern Drug Design)
Current Medicinal Chemistry The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
Current Cancer Therapy Reviews Mechanical Imaging - a Technology for 3-D Visualization and Characterization of Soft Tissue Abnormalities: A Review
Current Medical Imaging ESM-1: A Novel Tumor Biomaker and its Research Advances
Anti-Cancer Agents in Medicinal Chemistry Alternative Splicing and Tumor Progression
Current Genomics Brain-Skin Connection: Stress, Inflammation and Skin Aging
Inflammation & Allergy - Drug Targets (Discontinued) Adenovirus/PSA (Ad5-PSA) Vaccination for Prostate Cancer: Pre-Clinical and Clinical Development
Current Cancer Therapy Reviews Estrone (E1) Based Esters as Potential Inhibitors of Type 3 17β- hydroxysteroid Dehydrogenase (17β-HSD3) in the Treatment of Hormone-Dependent Prostate Cancer
Letters in Drug Design & Discovery Herbal Compounds and Toxins Modulating TRP Channels
Current Neuropharmacology Nuclear Architecture and Gene Expression in the Quest for Novel Therapeutics
Current Pharmaceutical Design Meet Our Co-Editor
Letters in Drug Design & Discovery LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers
Current Cancer Drug Targets